(Date:1/9/2009)...Inc., Horsham, PA announced that a new Hydrophili...ed to the company,s website that provides a forum ...an go to find the latest developments in device co...d coatings news. , Horsha...rsham, PA announced that a new Hydrophilic Coatin...
(Date:1/9/2009)...nd Peptide, a Massachusetts-based designer and pro... for drug and vaccine discovery organizations worl...mical solutions in the face of the global shortage...trategic usage of new solutions are two leading pe...dges. , Gardner, MA (PRWE...
(Date:1/9/2009)...re/ -- , - New Online Service Provides the ...s at Whatever Age , A new website has been ...esigned specifically to get rid of all examination...AID and it can be found at, http://www.befreefrom...struction, there and then, on how to get rid of ex...
(Date:1/8/2009)...stCall/ - Med-Emerg International Inc. (OTCBB:MDER...of health services, is pleased to announce that it...sly announced plan of arrangement (the "Arrangemen...l meeting of MedEmerg,s shareholders held in Toron...e meeting were in favour of the Arrangement. , Th...
Breaking Medicine News(10 mins):Health News:Blog Launched to Discuss Developments in Hydrophilic Coatings for Medical Devices 2Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 2Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 3Health News:Be Free From Exam Nerves 2Health News:Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc. 2(Date:1/6/2009)...swire-FirstCall/ -- , - Early Renewal of th...ember 2011 , - Expansion of the Scope of th...Ophthalmology , - Revised Commercial Terms ...o a Third Party , ExonHit Therapeutics (A...of its existing drug discovery collaboration with ...
(Date:12/30/2008)...ewswire/ -- The Coalition for 21st Century Medicin...enentech, Inc. on December 5, 2008, seeking to res...tic tests to physicians and patients. The request...arm patient care and rests on flawed scientific an...s to encourage the research, development, and comm...
(Date:12/17/2008)...t and validation of non-animal alternative test me...re/ -- MatTek Corporation today announced that the...ed the scientific validity of the Modified EpiDerm...g. ESAC concluded that the Modified EpiDerm SIT h...diction of skin irritating and non-irritating test...
(Date:12/17/2008)...l/ -- Delcath Systems, Inc. (Nasdaq: DCTH ) toda...h.D., to Delcath,s Board of Directors. Dr. Contag...perience working with international and domestic i....com/cgi-bin/prnh/20081118/NY46990LOGO ) , ,... 2006 and served as CEO. Prior to starting Cobalt...
Breaking Medicine Technology:ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4EpiDerm's Skin Irritation Test Fully Validated in European Union 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Dragon retains leading investor relations firm 3999 1Dragon retains leading investor relations firm 3999 2Dragon retains leading investor relations firm 3999 3QuoNova Global Executive Appointments 3994 1QuoNova Global Executive Appointments 3994 2QuoNova Global Executive Appointments 3994 3QuoNova Global Executive Appointments 3994 4Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 1Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 2Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 3Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 4New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 1New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 2New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 3...ries, Inc. Today,Announced the Top Line Results of...) Study with the Compound Desmoteplase , Aachen (G...k,Exchange, Prime Standard: PA8) and its US partne...unced topline results of,the DIAS-2 (Desmoteplase ...Desmoteplase. The Phase III study was designed to,...
...tCall/ - Research,collaborators with Oncolytics Bi... a poster presentation covering REOLYSIN(R),clinic...Oncology,(ASCO) Annual Meeting, to be held June 1-...f Oncolytics, U.K. Phase I systemic,administration... Phase I Study of,Wild-Type Oncolytic Reovirus Adm...
Other Medicine Technology:Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: